63 related articles for article (PubMed ID: 2600605)
1. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
2. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW
Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model.
Rodolfo M; Salvi C; Bassi C; Parmiani G
Cancer Immunol Immunother; 1990; 31(1):28-36. PubMed ID: 2306753
[TBL] [Abstract][Full Text] [Related]
4. Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors.
Sensi M; Grazioli L; Rodolfo M; Parmiani G
Cancer Immunol Immunother; 1990; 31(1):37-43. PubMed ID: 2306754
[TBL] [Abstract][Full Text] [Related]
5. Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563.
Maekawa R; Matsumoto M; Kitagawa T; Harada M; Sato K
Cancer Immunol Immunother; 1986; 23(1):25-30. PubMed ID: 3490306
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.
Ootsu K; Gotoh K; Houkan T
Cancer Immunol Immunother; 1989; 30(2):71-80. PubMed ID: 2598180
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of combination of murine recombinant interferon beta, murine recombinant interferon gamma and human recombinant interleukin-2 in MethA-bearing mice.
Itoh T; Sakata Y; Yoshida Y; Tsushima K; Suzuki H; Saitoh S; Tamura Y; Ogasawara H; Sugimoto N; Takemori H
Cancer Immunol Immunother; 1990; 32(2):88-94. PubMed ID: 2126986
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft.
Hubbell HR; Vargas HE; Tsujimoto KL; Gibson GD; Pequignot EC; Bigler RD; Carter WA; Strayer DR
Cancer Immunol Immunother; 1992; 35(3):151-7. PubMed ID: 1638550
[TBL] [Abstract][Full Text] [Related]
9. Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.
Saito M; Ichimura O; Kataoka M; Moriya Y; Ueno K; Sugawara Y; Nanjo M; Ishida N
Cancer Immunol Immunother; 1986; 22(3):161-8. PubMed ID: 2425968
[TBL] [Abstract][Full Text] [Related]
10. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.
Harada M; Matsuzaki G; Shinomiya Y; Kurosawa S; Ito O; Okamoto T; Takenoyama M; Sumitika H; Nishimura Y; Nomoto K
Cancer Immunol Immunother; 1994 May; 38(5):332-8. PubMed ID: 8162615
[TBL] [Abstract][Full Text] [Related]
11. Effect of indomethacin on tumor-infiltrating lymphocytes of a spontaneously developed murine mammary adenocarcinoma.
Chao TY; Chu TM
Cancer Immunol Immunother; 1989; 30(3):158-64. PubMed ID: 2598184
[TBL] [Abstract][Full Text] [Related]
12. Effects of cyclosporin on C57BL/6 splenocytes before and after culture with high-dose recombinant interleukin-2: implications for immunosuppression with cyclosporin.
Sutherland F; Borkenhagen K; Temple L; Bryant LD; Lafreniere R
Cancer Immunol Immunother; 1990; 31(5):312-20. PubMed ID: 2376049
[TBL] [Abstract][Full Text] [Related]
13. Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2.
Eisenthal A
Cancer Immunol Immunother; 1990; 31(6):342-8. PubMed ID: 2386979
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer.
Scudeletti M; Filaci G; Imro MA; Motta G; Di Gaetano M; Pierri I; Tongiani S; Indiveri F; Puppo F
Cancer Immunol Immunother; 1993 Jul; 37(2):119-24. PubMed ID: 8391391
[TBL] [Abstract][Full Text] [Related]
15. Induction of cytotoxicity from fresh splenocytes after in vivo administration of cyclophosphamide. Importance of long-term culture with high-dose recombinant interleukin-2.
Kim R; Lafreniere R; Borkenhagen K; Bryant LD
Cancer Immunol Immunother; 1989; 30(5):283-8. PubMed ID: 2624921
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor activity of interleukin-2 and cimetidine against syngeneic murine tumor.
Nakajima I; Chu TM
Cancer Immunol Immunother; 1991; 33(1):9-14. PubMed ID: 2021961
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2: hope in cases of cisplatin-resistant tumours.
Bernsen MR; Van Der Velden AW; Everse LA; Dullens HF; Den Otter W; Heintz AP
Cancer Immunol Immunother; 1998 Mar; 46(1):41-7. PubMed ID: 9520291
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.
Rubin M; Mokyr MB
Cancer Immunol Immunother; 1993; 36(1):37-44. PubMed ID: 8422666
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
[TBL] [Abstract][Full Text] [Related]
20. 7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine.
Pope BL; Sigindere J; Chourmouzis E; MacIntyre P; Goodman MG
Cancer Immunol Immunother; 1994 Feb; 38(2):83-91. PubMed ID: 8306370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
